A systematic review was performed for evaluation of the performance of CardioCel® in cardiac surgery. The review included all studies published from January 2013 to December 2020. We conclude that CardioCel is a strong, flexible tissue substitute with good handling characteristics and a low incidence of thrombosis, aneurysm formation, infection, or structural degeneration. It can be used for a variety of intracardiac and extracardiac repairs of congenital heart defects in all age groups with good durability at mid-term follow-up. However, the use of CardioCel in certain positions requires caution. Information on the long-term performance of CardioCel is lacking.
ThubrikarMJDeckJDAouadJNolanSP. Role of mechanical stress in calcification of aortic bioprosthetic valves. J Thorac Cardiovasc Surg. 1983;86(1):115‐125.
2.
MillerDCStinsonEBOyerPE, et al.The durability of porcine xenograft valves and conduits in children. Circulation. 1982;66(3):I172‐I185.
3.
DeiwickMGlasmacherBBabaHA, et al.In vitro testing of bioprostheses: influence of mechanical stresses and lipids on calcification. Ann Thorac Surg. 1998;66(6):S206‐S211.
4.
Huang-LeeLLCheungDTNimniME. Biochemical changes and cytotoxicity associated with the degradation of polymeric glutaraldehyde derived crosslinks. J Biomed Mater Res. 1990;24(9):1185‐1201.
5.
NeethlingWMYadavSHodgeAJGlancyR. Enhanced biostability and biocompatibility of decellularized bovine pericardium, crosslinked with an ultra-low concentration monomeric aldehyde and treated with ADAPT. J Heart Valve Dis. 2008;17(4):456‐463. Discussion 464.
6.
SchoenFJLevyRJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg. 2005;79(3):1072‐1080.
7.
RossiMABraileDMTeixeiraMDSouzaDRPeresLC. Lipid extraction attenuates the calcific degeneration of bovine pericardium used in cardiac valve bioprostheses. J Exp Pathol (Oxford). 1990;71(2):187‐196.
8.
CunananCMCabilingCMDinhTT, et al.Tissue characterization and calcification potential of commercial bioprosthetic heart valves. Ann Thorac Surg. 2001;71(5):S417‐S421.
9.
BrizardCPBrinkJHortonSBEdwardsGAGalatiJCNeethlingWM. New engineering treatment of bovine pericardium confers outstanding resistance to calcification in mitral and pulmonary implantations in a juvenile sheep model. J Thorac Cardiovasc Surg. 2014;148(6):3194‐3201.
10.
NeethlingWMLPulsKReaA. Comparison of physical and biological properties of CardioCel® with commonly used bioscaffolds. Interact Cardiovasc Thorac Surg. 2018;26(6):985‐992.
11.
NeethlingWMHodgeAJClodePGlancyR. A multi-step approach in anti-calcification of glutaraldehyde-preserved bovine pericardium. J Cardiovasc Surg (Torino). 2006;47(6):711‐718.
12.
NeethlingWBrizardCFirthLGlancyR. Biostability, durability and calcification of cryopreserved human pericardium after rapid glutaraldehyde-stabilization versus multistep ADAPT(R) treatment in a subcutaneous rat model. Eur J Cardiothorac Surg. 2014;45(4):e110‐e117.
13.
SalamehAGreimannWVondrysDKostelkaM. Calcification or not. This is the question. A 1-year study of bovine pericardial vascular patches (CardioCel) in minipigs. Semin Thorac Cardiovasc Surg. 2018;30(1):54‐59.
14.
SobierajMCudakEMrówczyńskiWNałęczTKWesterskiPWojtalikM. Application of the CardioCel bovine pericardial patch—a preliminary report. Kardiochir Torakochirurgia Pol. 2016;13(3):210‐212.
15.
TomšičABissessarDDvan BrakelTJMarsanNAKlautzRJMPalmenM. Initial experience and early results of mitral valve repair with CardioCel pericardial patch. Ann Thorac Surg. 2018;106(4):1241‐1244.
16.
NeethlingWMStrangeGFirthLSmitFE. Evaluation of a tissue-engineered bovine pericardial patch in paediatric patients with congenital cardiac anomalies: initial experience with the ADAPT-treated CardioCel(R) patch. Interact Cardiovasc Thorac Surg. 2013;17(4):698‐702.
17.
NeethlingWReaAForsterGBhirangiK. Performance of the ADAPT-treated CardioCel® scaffold in pediatric patients with congenital cardiac anomalies: medium to long-term outcomes. Front Pediatr. 2020;8:198.
18.
BellDPrabhuSBettsK, et al.Durability of tissue-engineered bovine pericardium (CardioCel®) for a minimum of 24 months when used for the repair of congenital heart defects. Interact Cardiovasc Thorac Surg. 2019;28(2):284‐290.
19.
PrabhuSArmesJEBellD, et al.Histologic evaluation of explanted tissue-engineered bovine pericardium (CardioCel). Semin Thorac Cardiovasc Surg. 2017;29(3):356‐363.
20.
DeutschOBruehlFCleuziouJ, et al.Histological examination of explanted tissue-engineered bovine pericardium following heart valve repair. Interact Cardiovasc Thorac Surg. 2020;30(1):64‐73.
21.
PavyCMichielonGRobertusJLLacour-GayetFGhezO. Initial 2-year results of CardioCel® patch implantation in children. Interact Cardiovasc Thorac Surg. 2018;26(3):448‐453.
22.
BellDBettsKJustoR, et al.Multicenter experience with 500 CardioCel implants used for the repair of congenital heart defects. Ann Thorac Surg. 2019;108(6):1883‐1888.
23.
WigginsLMMimicBIssittR, et al.The utility of aortic valve leaflet reconstruction techniques in children and young adults. J Thorac Cardiovasc Surg. 2020;159(6):2369‐2378.
24.
NordmeyerSMurinPSchulzA, et al.Results of aortic valve repair using decellularized bovine pericardium in congenital surgery. Eur J Cardiothorac Surg.2018;54(6):986‐992.
25.
NordmeyerSKretzschmarJMurinP, et al.ADAPT-treated pericardium for aortic valve reconstruction in congenital heart disease: histological analysis of a series of human explants. Eur J Cardiothorac Surg. 2019;56(6):1170‐1177.
26.
ChiversSCPavyCVajaRQuartoCGhezODaubeneyPEF. The Ozaki procedure with CardioCel patch for children and young adults with aortic valve disease: preliminary experience—a word of caution. World J Pediatr Congenit Heart Surg. 2019;10(6):724‐730.
27.
VashiAVWhiteJFMcLeanKM, et al.Evaluation of an established pericardium patch for delivery of mesenchymal stem cells to cardiac tissue. J Biomed Mater Res A. 2015;103(6):1999‐2005.
28.
ReulGJJr.CooleyDADuncanJM, et al.Valve failure with the Ionescu-Shiley bovine pericardial bioprosthesis: analysis of 2680 patients. J Vasc Surg. 1985;2(1):192‐204.
29.
ManjiRALeeWCooperDKC. Xenograft bioprosthetic heart valves: past, present and future. Int J Surg. 2015;23(Pt B):280‐284.
30.
JalalZGalmicheLLebeauxD, et al.Selective propensity of bovine jugular vein material to bacterial adhesions: an in-vitro study. Int J Cardiol. 2015;198:201‐205.
31.
KostolnyMMalikTBonelloB. Infective endocarditis associated with varicella zoster virus following aortic valve repair. World J Pediatr Congenit Heart Surg. 2020;11(4):NP148‐NP150.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
